U.S. Markets close in 6 hrs 12 mins

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
130.783+0.333 (+0.255%)
As of 9:48AM EDT. Market open.
People also watch
  • Still trying to figure out what's going on at Lilly. Still don't know what FDA objected to. But I have a thought.

    Plugged a few figures into the AHA heart attack risk calculator. The reduction in HDL with JAK2 inhibition could lead to a couple tenths of a percent increase in heart attack risk over 10 years (other things being equal, which of course they aren't). There is no imaginable way that this level of risk increase could be rejected at the 95% confidence level with 10,000 patient-years of data (ESPECIALLY if the risk is expected to be concentrated in out-years and few of those patient-years are from more than 4 years of exposure). Normally, FDA doesn't get hung up on a theoretical adverse event that hasn't actually been observed (and make no mistake, increased rate of heart attacks has NOT been observed in the Lilly trials). But Olumiant is a drug meant to be taken for many years by many patients with a condition not generally considered life-threatening. And FDA got two black eyes over the COX-2 inhibitors, anti-arthritis drugs that increased risk of heart attacks (as it turns out years later, by a tiny amount that was clearly outweighed by other AEs that they avoided, but it was quite the scandal at the time). If 100,000 people take Olumiant, a 0.1% extra risk of heart attack (percent of total, not relative to baseline risk) is 100 in 10 years. That's a sizeable risk for FDA, and of course, if you start talking about it. everyone taking Olumiant who suffers a heart attack (that's north of 4% over 10 years) is going to sue, so Lilly is justified in treading carefully.

    This small theoretical risk clearly wasn't taken account of in dose determination, so that part fits.

    Lilly, of course, wants the largest possible label indication AND protection from lawsuits. So it would make sense for them to be doing every imaginable analysis of subgroups contributing to the risk estimate and of experience with Jakafi (which affects blood lipids worse and doesn't seem to have an adverse heart effect--but lowers platelets, which independently counters that risk). The desired outcome would be to come up with zero-CV-risk and excessive-CV-risk subgroups, and a risk mitigation strategy that wouldn't need 10+ years of testing.

    Just guessing, of course. And I'm not sure how this would tie in with late completion of the '5705 trial. But the combination of having to satisfy both FDA and the personal injury lawyers could make the delay continue several more months.
  • Tommy, J'off, B and Yellow...hurry....hurry...time to run over to Vertex...up over $35 on Stage 1 and 2 news just out. Whoa, way over valued and GILD won't be able to touch them now....and you must harass those because I'm sure those longs are way out of touch about its current valuation!!! Run Tommy, J'off, B and Yellow Run!!
  • IBB on fire, S&P up, ow up NAZ up,

    LONGS PUMPING doom and gloom to the shorts and

    INcyte will go red today
  • maddi, says this man is a hack on the article he wrote on incyte, seems like his credentials are as good as any worthless analysts out there , next we will here that Jacosa knows more than the analysts

    Michael Kramer is the Founder of Mott Capital Management and runs MCM's actively managed long-only Thematic Growth Portfolio

    Read more: Michael Kramer Bio | Investopedia http://www.investopedia.com/contributors/67544/#ixzz4nCIXHjf6
    Follow us: Investopedia on Facebook

    Michael Kramer Bio | Investopedia
  • Touched back into the $120's today. But I bet none of the dreamers are willing to call it volatility still. They saw it touch $135 last week and thought $140 was a sure thing, and from there surely $150, and then it's a given that some bold and daring CEO would risk his career, future and dignity by offering $300/share. The dreamers just don't appreciate the absurdity of that buyout scenario.

    If there's a buyout it'll happen at a reasonable price somewhere near reasonable P/E. No one's paying for the rights to a phantom pipeline and then pouring even more money into that pipeline with childish hopes that it's all going to turn up spades. Right now a generous buyout would be $10 billion which still puts INCY at an astonishing P/E of 100, with a premium at a price of $50-60. If you want to include any near future revenues, then add $20-30 for an even high premium offer. That's an offer based on cold hard earnings as all offers should be. Those are the realities of this business.

    There have been several ostensibly positive developments but the price stagnates and that's because none of those developments make INCY worth 200-300x earnings. You dreamers still haven't grasped the difference between price and value. The one thing that can make INCY really worth the current market cap is if this year they magically earn about $1 billion, compared to last year's $100 million. Unless that happens INCY won't hold this market cap.
  • Tom stated INCY red -- looks like he is right again.

    Tom = 100%
    4 stooges = all zeros 00000000000000000000000000000
  • Attention, attention, Maddison! When all you do is just throw out some fantasy buyout price it doesn't mean you have any meaningful understanding of INCY's value. If what I said is clueless then please for the love of decency tell me why you are clue-ful.

    Don't hide like a coward this time. Why don't you stand up and really show everyone here why I'm wrong and you're right? Here's what you can do to really demonstrate to everyone why your estimates make sense.

    I'll keep it simple: The reality is INCY only earned $100 million but the cap is swollen 200-300x. It's swollen on buyout rumors. If you think INCY will be bought at $200-$300-$400/share, then tell us how much earnings justifies that price? Or do you really think with only $100 million earnings a buyout price of $300 is justified? Because at $300/share the buyer won't break even for 600 years, assuming technology doesn't improved and not accounting for inflation.

    But you and your pump squad love to say a buyout price won't be based on earnings, right? LOL Then what the devil is a buyout price based on? Phantom earnings? Phantom drugs that aren't approved? Why on earth would a buyer pay a premium for drugs that don't exist? Are buyers lining up to pay a premium so they can risk even more money on developing pipelines? Why wouldn't these buyers just let INCY take all the risk on the pipeline in the first place? Why would these buyers pay a premium to buy all that risk?

    Or is your clue-ful assumption that once the jakafi market matures then INCY will suddenly be making orders of magnitude greater earnings? Really? Is your buyout price based on jakafi alone? Besides the competitors in development for jakafi's jak inhibitor market, do you realize how fast immuno is developing? Who knows what new drugs will exist in 5 years. Jakafi is a risk all by itself. Jakafi might never see a mature market. That's the reality. Any buyers will inherit that risk, they have to think 10-20 years ahead. Breaking even for them means losing money. Even supposing jakafi reaches maturity, what's that market worth? Jakafi doesn't help anywhere near the total population of that market. And more than 80% of patients quit jakafi in 3-5 years. Show me the money.

    So lay it all out for us Maddison:

    1) What is your buyout price estimate and how much earnings does INCY have to earn to justify it?
    2) Is that price pinned to just jakafi's earnings? Or what else and in what proportion?
    3) How long will it take to reach those earnings goals?
    4) Most importantly, does earnings just not matter at all to you? And you just expect a buyer to assume all the risk while also paying a several-hundred-times premium? Is it the buyer's privilege to just throw cash at INCY and swallow all that risk? Why don't they just do that with even cheaper companies? What makes INCY so essential that buyers should pay a premium for a mountain of risk? Would you do that with YOUR money?

    Your idea of a buyout is gaseous. You don't actually have any idea or metric of what the price should be based on. All you think is that INCY made some money on jakafi and INCY has a pipeline, and that's it, and that's automatically worth 200x or 300x or 400x earnings or more. But the actual pipeline and the actual earnings, the real drivers of business, you left out all that stuff in some vague cloud of blind enthusiasm, but you don't really have any idea, do you?

    What I said is the sound market standard. P/E of 20-40 is solid, and that puts INCY at $20/share. Even 100 P/E for a developing company, depending on the company and market, could be palatable... and that puts INCY at $50/share. But 300 P/E puts INCY at $150/share and that isn't just an overestimate, it's comic, it's really hyperinflation. And yet some of you even believe it should be 400 P/E. BASED ON WHAT?

    Maddison, don't dodge these questions. Speak up for the longs. Give them some ground to stand on. Don't let jacosa beat you to it. Stand up for yourself. If jacosa wants to answer he should wait till after you.
  • The shorts are getting nervous, crying and spitting like pigs going to the slaughter! 😁🤣😁😁😁😁😁😁😁😎💣🖕🏼
  • Please everyone stop replying to "B". If the only thing you can bring to this MB is a cartoon maybe you should go back to school and get an education..... You really are not funny.....it only shows your immaturity....
  • NVS Jakavi sales $186 million compared to $162 for first quarter! WOW! Won't be long and NVS will be on a billion dollar a year run rate...
  • still wondering what has happened to the loud mouth, name calling, finger pointing, worthless excuse for an indiviuals, pumping longs have gone to ??????
  • so longs, i have noticed very slight rebuttals of your hyping by Jacosa, seems you have over look them and keep right on pumping, did any of you read what he wrote on bari sales today?

    here is a reminder, of just a few of your hyping wrongs in the recent past

    AARC with 23 abstracts......hyped pumping, stock goes down
    ASCO with 15 abstracts ...hyped pumping, stock goes down
    Bari approval in the US, FDA SLAMS the door....stock pummeled

    now comes the insane pumping on how MASSIVE the bari sales are going to be in the EU......do any of you worthless pumpers committ on what Jacosa says???????

    I hear how good the sales are for Ruxo for NVS......so it has to translate into huge sales for it in the US.... ok so what.....Incyte is spending money so fast that Ruxo needs to do nearly $1.5 Billion to stay ahead of the spending curve. I also hear about all the NEW opportunities for RUXO, there is not much happening, what is it???? when will it come to mkt? potentially 2019 or 2020......by then there could be a ruxo competitor...who cares

    it is nearing 70 business days on bari FDA crl, with no news, nearly 100 days in total......hmmmm quickly becoming a THIRD of a year with out a peep. Jacosa talks about it is worse not knowing anything , than having a decision, again pumping longs are not listening. so what happens if they want another p3 study, that is far from the gentler, kinder FDA, especially with the SWIFTNESS of what has happened in the UK and Japan. This will likely cause another huge bear raid in shares with at least another $20 a share gone. Abbv is not far behind with their jak drug for RA, and longer it takes for an approval the less in roads Lilly will ever make in RA...as no one knows the RA market and has a better salesforce than ABBV.
  • Maybe INCY could come up with a drug cure for NOROVIRUS. It would be a hit for investment billionaire Ackman. He would buy into INCY so that it would solve his problems at Chipotle. With every burrito you get a pill mixed in.

    fast track this one threw the fda.
  • B is trying hard... your days are ending... jakafi sales by nvs show that drug is being prescribed and sales rate show a nice improvement. That you can extrapolate to jakafi us sales. Now you will see olumiant sales tick up when lly report their earnings!
  • waiting longs, why are shorts SUPPOSED to be SCREAMING???

    oh, Gilead must be buying incyte now, cause VRTX is now to expensive.....biggest oke i have ever heard
  • waiting , been waiting for 70 days, yet nothing, zip, zilch, nichts, nada ............ and it is TRULY OVER 100 days

    pump squad has even given up

  • here it comes the sub, pick tom and go for a trip and dive hard because you won't like to see the 'volatility' when incyte again touches 150 level... can tom and sub comment the reality of jakafi sales, a great product from incyte with an excelent sales partner with even more potential in the near future like you know in the trials that are going on!
  • Tomorrow is the nvs earnings day...look out for jakafi sales! Shorts look out, big bear trap!
  • wall st is getting tired of waiting, nearing 70 business days, REALLY nearly 100 and not a word on baricitinib, oh the gentler , kinder FDA, HAHA
    IBB up, NAz up, S&P UP, INCY RED yet again, way more red days on green mkt days